Palatin Technologies (PTN) Depreciation & Amortization (CF) (2010 - 2026)
Palatin Technologies' (PTN) quarterly Depreciation & Amortization (CF) came in at $16952.0 in Q1 2026, down 68.2% YoY from $53304.0 in Q1 2025, and up 17.82% on a QoQ basis from $14388.0 in Q4 2025.
Palatin Technologies (PTN) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $16952.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 68.2% year-over-year to $16952.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98720.0 (down 65.71% YoY) and the FY2025 annual result came in at $258917.0, down 23.64% from the prior year.
- Depreciation & Amortization (CF) improved to $16952.0 in Q1 2026, from $14388.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $87357.0 in Q3 2023 to a low of $14387.0 in Q3 2025.
- A 5-year average of $59915.5 and a median of $69778.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 374.76% — and 2025, when it tumbled 82.19%.
- Tracing PTN's Depreciation & Amortization (CF) over 5 years: stood at $69778.0 in 2022, then climbed by 21.39% to $84703.0 in 2023, then dropped by 15.2% to $71830.0 in 2024, then tumbled by 79.97% to $14388.0 in 2025, then climbed by 17.82% to $16952.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $16952.0 (Q1 2026), $14388.0 (Q4 2025), and $14387.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | 16,952.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,952.00 |
| Mar 31, 2026 | 16,952.00 |
| Dec 31, 2025 | 14,388.00 |
| Dec 31, 2025 | 14,388.00 |
| Sep 30, 2025 | 14,387.00 |
| Sep 30, 2025 | 14,387.00 |
| Jun 30, 2025 | 52,993.00 |
| Jun 30, 2025 | 52,993.00 |
| Mar 31, 2025 | 53,304.00 |
| Mar 31, 2025 | 53,304.00 |
| Dec 31, 2024 | 71,830.00 |
| Dec 31, 2024 | 71,830.00 |
| Sep 30, 2024 | 80,790.00 |
| Sep 30, 2024 | 80,790.00 |
| Jun 30, 2024 | 81,960.00 |
| Jun 30, 2024 | 81,960.00 |
| Mar 31, 2024 | 85,055.00 |
| Mar 31, 2024 | 85,055.00 |
| Dec 31, 2023 | 84,703.00 |
| Dec 31, 2023 | 84,703.00 |